Y0000046
β-雌二醇 17-戊酸酯
European Pharmacopoeia (EP) Reference Standard
别名:
1,3,5(10)-雌三烯-3,17β-二醇 17-戊酸酯
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H32O3
化学文摘社编号:
分子量:
356.50
Beilstein:
2480357
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
estradiol
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CCCCC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C
InChI
1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3
InChI key
RSEPBGGWRJCQGY-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Estradiol valerate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险分类
Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
法规信息
涉药品监管产品
此项目有
A Teichmann
Climacteric : the journal of the International Menopause Society, 6 Suppl 2, 17-23 (2003-12-13)
The particular features of the pharmacology of a new continuous regimen for hormone replacement therapy containing 2 mg estradiol valerate (E2V) and 2 mg dienogest (DNG) (Climodien, Schering AG, Berlin, Germany) depend largely on its progestogenic component. Dienogest has the
C Egarter et al.
Acta obstetricia et gynecologica Scandinavica, 75(4), 386-393 (1996-04-01)
Two sequential hormone replacement regimens, containing either estradiol valerate plus medroxyprogesterone acetate (E2V/MPA) or conjugated estrogens plus medrogestone (CE/MED), were compared with respect to effects on climacteric symptoms, lipid metabolism, and hemostasis. In an open, multicenter study, 51 perimenopausal women
R M Machado-de-Sena et al.
Photodiagnosis and photodynamic therapy, 11(3), 275-282 (2014-05-06)
Vaginal candidiasis (VC) is a disease that affects thousands of women of childbearing age, mainly caused by Candida albicans fungus. Photodynamic therapy (PDT) uses photosensitizing substances that are nontoxic in the dark, but able to produce reactive oxygen species when
Franca Fruzzetti et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 28(5), 400-408 (2012-04-04)
Natural estrogens such as estradiol (E(2)) or its valerate ester (E(2)V) offer an alternative to ethinyl estradiol (EE). E(2)-containing combined oral contraceptives (COCs) have demonstrated sufficient ovulation inhibition and acceptable contraceptive efficacy. However, earlier formulations were generally associated with unacceptable
Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
B von Schoultz
Climacteric : the journal of the International Menopause Society, 6 Suppl 2, 24-32 (2003-12-13)
A combination of 2 mg estradiol valerate with 2 mg dienogest (E2V/DNG) (Climodien, Schering AG, Berlin, Gemany) is the first continuous combined postmenopausal hormone replacement therapy (HRT) preparation to contain a progestogen with substantial antiandrogenic activity. A study of its
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持